<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691999</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00107216</org_study_id>
    <nct_id>NCT04691999</nct_id>
  </id_info>
  <brief_title>The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer</brief_title>
  <acronym>EFFECT-BC</acronym>
  <official_title>EFFECT-BC: The EFFECT of Intermittent Fasting on Body Composition in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate intermittent fasting after the treatment of breast&#xD;
      cancer with surgery and radiation therapy. All participants will either delay their first&#xD;
      meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting&#xD;
      period four times per week. Over six months, the innovative protocol will 1) assess&#xD;
      adherence, and is expected to 2) improve body composition, quality of life and inflammatory&#xD;
      and metabolic variables linked with outcomes after breast cancer treatment. The long-term&#xD;
      goal of this project is to incorporate this dietary strategy as a standard component of care&#xD;
      for breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to the intermittent fasting program</measure>
    <time_frame>6 months</time_frame>
    <description>as determined by the proportion of fasting days met divided by the total fasting days planned for each participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body fat</measure>
    <time_frame>baseline, 6 months</time_frame>
    <description>as measured by mean change in percent body fat between baseline and 6 months</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intermittent Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent Fasting</intervention_name>
    <description>16-18 hour fasting period four times per week</description>
    <arm_group_label>Intermittent Fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the&#xD;
             breast stage I-III&#xD;
&#xD;
          -  completed any chemotherapy prior to initiation of the trial (adjuvant endocrine&#xD;
             therapy is permitted)&#xD;
&#xD;
          -  BMI &gt; 25 kg/m2 or body fat% greater or equal to 31%&#xD;
&#xD;
          -  have a schedule amenable to nutrition and dietitian counseling described within the&#xD;
             study protocol as determined by the treating radiation oncologist&#xD;
&#xD;
          -  have access to the internet and email with capability to join Zoom calls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic breast cancer&#xD;
&#xD;
          -  Currently receiving chemotherapy&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes, defined as systolic blood pressure over 149,&#xD;
             diastolic blood pressure over 99, or hemoglobin A1c greater than 8.9.&#xD;
&#xD;
          -  Diabetic condition requiring the usage of insulin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>participant eligibility is not based on self-representation of gender identity</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Champ, MD CSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eileen Duffy, RN BSN</last_name>
    <phone>919 668 3726</phone>
    <email>Eileen.Duffy@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Cahill, BNS OCN CCRP</last_name>
    <phone>(919) 668-5211</phone>
    <email>Joan.Cahill@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eileen Duffy, RN BSN</last_name>
      <phone>919-668-3726</phone>
    </contact>
    <investigator>
      <last_name>Colin Champ, MD CSCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intermittent fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

